Association of GB virus C (GBV-C)/hepatitis G virus (HGV) with haematological diseases of different malignant potential

Pavlova, Borislava G.; Heinz, R.; Selim, U; Tüchler, Heinz; Pittermann, E.; Eder, Gerald

doi:10.1002/(sici)1096-9071(199904)57:4<361::aid-jmv6>3.0.co;2-o

Cited by 20 publications

(20 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A high incidence of past GBV‐C infection might be present in patients with B cell‐NHLs . Some studies suggested an association between GBV‐C infection and NHL , but other authors could not make the same observation . Many of these studies comprised a small number of patients or lacked of controls, so this still represents a controversial issue.…”

Section: Discussionmentioning

confidence: 99%

Hepatitis C virus and GBV‐C virus prevalence among patients with B‐cell lymphoma in different European regions: a case‐control study of the International Extranodal Lymphoma Study Group

Guidicelli

López‐Guillermo

Falcone

et al. 2011

Hematological Oncology

View full text Add to dashboard Cite

Hepatitis C virus (HCV) infection is associated with some B-cell non-Hodgkin lymphoma (B cell-NHLs). Patients with HCV infection frequently show co-infections with GB virus C (GBV-C, formerly known as hepatitis G virus), and some studies have suggested a higher incidence of GBV-C infection in patients with B cell-NHLs. The aim of this study was to prospectively evaluate the association between HCV and/or GBV-C infection and B cell-NHLs in different geographic areas. One hundred thirty-seven lymphoma cases and 125 non-lymphoma matched controls were enrolled in an international case-control study conducted in Switzerland (Bellinzona), Spain (Barcelona) and England (Southampton) on samples collected from 2001 to 2002. In Bellinzona (41 cases and 81 controls), the overall prevalence of HCV was 3.3% (4.9% in NHLs), and the overall prevalence of GBV-C was 24% (22% in NHLs). In Barcelona (46 cases and 44 controls), the prevalence of HCV was 10% (8.7% in NHLs) and the prevalence of GBV-C 20% (13% in NHLs). There was no statistically significant difference in the frequency of both infections between patients with NHL and controls. In Southampton, 50 NHL cases were analysed, none of them was found to be HCV-positive; therefore, no control group was analysed and GBV-C analysis was not performed, too. Both in Bellinzona and in Barcelona, the seropositivity rate was significantly lower for HCV than for GBV-C, suggesting that their transmission can be independent. The incidence of HCV was significantly higher in Barcelona than that in Bellinzona. This study confirmed the existence of marked geographic differences in the prevalence of HCV in NHL but cannot provide any significant evidence for an association between HCV and/or GBV-C and B-cell NHLs.

show abstract

Section: Discussionmentioning

confidence: 99%

Hepatitis C virus and GBV‐C virus prevalence among patients with B‐cell lymphoma in different European regions: a case‐control study of the International Extranodal Lymphoma Study Group

Guidicelli

López‐Guillermo

Falcone

et al. 2011

Hematological Oncology

View full text Add to dashboard Cite

show abstract

“…Pavlova et al . (Pavlova et al . 1999) investigated two groups of patients, one with clonal stem cell disease with long latency period (myelodysplasia, myeloproliferative disease) and one with malignant haematological diseases (Hodgkin's lymphoma, non‐Hodgkin's lymphoma, acute leukaemia, multiple myeloma).…”

Section: Detection Of Gbv‐c/hgvmentioning

confidence: 99%

“…The prevalence of GBV‐C/HGV RNA in the group of oncological cases (72%) was significantly higher ( P = 0.02) than in the patients with clonal stem cell diseases (28%). A correlation could not be confirmed between GBV‐C/HGV and liver enzyme levels, blood transfusions, chemotherapy, or viral co‐infection (Pavlova et al . 1999).…”

Section: Detection Of Gbv‐c/hgvmentioning

confidence: 99%

GB Virus C/Hepatitis G Virus (GBV‐C/HGV): still looking for a disease

Sathar

Soni²,

York

2000

Int J Experimental Path

View full text Add to dashboard Cite

GB Virus C and Hepatitis G Virus (GBV-C/HGV) are positive, single-stranded flaviviruses. GBV-C and HGV are independent isolates of the same virus. Transmission via the blood-borne route is the commonest mode, although vertical and sexual transmission is well documented. GBV-C/HGV is distributed globally; its prevalence in the general population is 10 fold higher in African countries than in non-African countries. High prevalences of GBV-C/HGV have been found in subjects with frequent parenteral exposure and in groups at high risk of exposure to blood and blood products. The clinical significance of human infection with GBV-C/HGV is currently unclear. The virus can establish both acute and chronic infection and appears to be sensitive to interferon. Only some 12-15% of chronic Non-A, B, C hepatitis cases are infected with GBV-C/HGV. A direct association with liver pathology is still lacking and it is not yet clear as to whether GBV-C/HGV is indeed a hepatotropic virus. Current evidence suggests that the spectrum of association of GBV-C/HGV infection with extrahepatic diseases ranges from haematalogical diseases, aplastic anaemia, human immunodeficiency virus (HIV)-positive idiopathic thrombocytopenia and thalassemia, through to common variable immune deficiency and cryoglobunemia.

show abstract

“…HGV is also seen in malignant potential Hodgkin's lymphoma, non-Hodgkin's lymphoma, acute leukaemia. It was also seen in malignant potential Hodgkin's lymphoma, non-Hodgkin's lymphoma, acute leukaemia (Anthony, 2000;Tucker et al, 2000;Reshetiyak et al, 2008;Pavlova et al, 1999;Idilman et al, 2000;Keresztes et al, 2003).…”

Section: Different Results and Discussion On Global Studiesmentioning

confidence: 99%

Hepatitis G virus (HGV): where we stand and what to do?

Ahmed

2011

IJIS

View full text Add to dashboard Cite

Hepatitis G virus was identified in 1995. Some work was done on HGV until 1997 and the FDA declared it as a non-harmful virus. This resulted in no screening of virus for blood donors and bags from 1997 until today. A review of scientific literature of the last 16 years, majority identify with polymerase chain reaction (PCR) has shown that HGV is quite prevalent around the globe with low to high prevalence in different countries among blood donors and other groups. It was found to be associated in hepatitis, cirrhosis of the liver and possibly present in hepatocellular carcinoma. It was also seen in hematological disorders and hematological malignancies. It is advisable that screening of blood is better than transferring HGV ignorantly to blood recipients as it was done before, where we did transfer HCV to many individuals which resulted in a lot of morbidities and mortalities.

show abstract

Association of GB virus C (GBV-C)/hepatitis G virus (HGV) with haematological diseases of different malignant potential

Cited by 20 publications

References 32 publications

Hepatitis C virus and GBV‐C virus prevalence among patients with B‐cell lymphoma in different European regions: a case‐control study of the International Extranodal Lymphoma Study Group

Hepatitis C virus and GBV‐C virus prevalence among patients with B‐cell lymphoma in different European regions: a case‐control study of the International Extranodal Lymphoma Study Group

GB Virus C/Hepatitis G Virus (GBV‐C/HGV): still looking for a disease

Hepatitis G virus (HGV): where we stand and what to do?

Contact Info

Product

Resources

About